13 completed. 13 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 4 | Completed 4 |
Follow Opioid Use Disorder: new trials by email Literature Review of Opioid Use Disorder trials Research Report on Opioid Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder INDV-2000, Placebo - Opioid Use Disorder | Phase 2 | Completed | Indivior Inc. | 300 | 2024-06-10 | 2025-12-16 |
| Cannabidiol in the Treatment of Opioid Use Disorder Placebo, Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg - Opioid Use Disorder | Phase 2 | Completed | Yasmin Hurd | 76 | 2023-10-04 | 2026-06-18 |
| Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Placebo, Auvelity - Addiction, Opioid Use | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | 18 | 2023-09-18 | 2026-08-19 |
| Suvorexant for Opioid/Stimulant Co-use Suvorexant (dual orexin receptor antagonist), Placebo - Opioid Use Disorder, Stimulant Use Disorder | Phase 2 | Completed | Johns Hopkins University | 20 | 2022-12-01 | 2025-12-23 |
| Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl Suvorexant, Placebo - Suvorexant, Placebo | Phase 2 | Completed | Johns Hopkins University | 76 | 2022-03-30 | 2026-08-10 |
| Reducing Pain and Opioid Use With CBD Cannabidiol, Placebo - Opioid Use Disorder | Phase 2 | Completed | University of Colorado, Denver | 126 | 2022-03-08 | 2025-12-12 |
| Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder Lemborexant, Placebo, Buprenorphine-naloxone - Drug Interaction, Analgesics | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | 18 | 2021-05-03 | 2024-11-13 |
| Neuroimaging and CBD for Opioid Use Disorder Cannabidiol (CBD), Placebo - Heroin Abuse, Opioid Use Disorder | Phase 2 | Completed | Yasmin Hurd | 66 | 2020-11-12 | 2025-10-27 |
| Oral Cannabidiol for Opioid Withdrawal Epidiolex, Placebo - Opioid Withdrawal, Opioid Craving | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 3 | 2020-11-01 | 2023-08-29 |
| A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists. Intravenous Challenge Drug - Opioid Use Disorder | Phase 2 | Completed | New York State Psychiatric Institute | 16 | 2018-03-15 | 2023-09-07 |
| Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose - Heroin Dependence, Opioid Use Disorder | Phase 1 / Phase 2 | Completed | Wayne State University | 26 | 2016-12-01 | 2020-11-10 |
| Phase II Pharmacokinetics Study of CAM2038 CAM2038 - Opioid Use Disorder, Chronic Pain | Phase 2 | Completed | Braeburn Pharmaceuticals | 66 | 2015-02-01 | 2020-04-30 |
| Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder Buprenorphine, buprenorphine and naloxone, hydromorphone - Opioid Use Disorder | Phase 2 | Completed | Indivior Inc. | 39 | 2013-11-01 | 2018-04-24 |
Opioid-Related Disorders (13) · Substance-Related Disorders (3) · Heroin Dependence (2) · Behavior, Addictive (1) · Chemically-Induced Disorders (1) · Chronic Pain (1) · Marijuana Abuse (1) · Narcotic-Related Disorders (1) · Pain (1) · Sleep Initiation and Maintenance Disorders (1)
Mental Disorders (13) · Chemically-Induced Disorders (12) · Narcotic-Related Disorders (12) · Substance-Related Disorders (10) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Behavior (1) · Compulsive Behavior (1) · Dyssomnias (1) · Impulsive Behavior (1) · Nervous System Diseases (1) · Pain (1) · Sleep Disorders, Intrinsic (1) · Sleep Wake Disorders (1)
Cannabidiol (4) · Buprenorphine (3) · Buprenorphine, Naloxone Drug Combination (2) · Hydromorphone (2) · suvorexant (2) · Naloxone (1) · Orexin Receptor Antagonists (1) · Oxycodone (1) · Oxymorphone (1) · Saline Solution (1) · lemborexant (1)
Johns Hopkins University (3) · Indivior Inc. (2) · Virginia Commonwealth University (2) · Yasmin Hurd (2) · Braeburn Pharmaceuticals (1) · New York State Psychiatric Institute (1) · University of Colorado, Denver (1) · Wayne State University (1)
United States (13)
Yasmin Hurd, PhD (2) · Andrew S Huhn, Ph.D. (1) · Cecilia L Bergeria, PhD (1) · Frederick G Moeller (1) · Frederick G Moeller, MD (1) · James Sullivan (1) · Jennifer Ellis, Ph.D. (1) · Mark Greenwald, PhD (1) · Sandra D Comer, PhD (1)
PMID 26650971, PMID 36467036, PMID 37584841, PMID 42113179
5UG1DA050207 (1), UG1DA050207 (1), UH3DA048734 (1)